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Objective: To determine the in vitro chemosensitivity of feline injection site-associated sarcoma 
(FISAS) cells to carboplatin concentrations generated by elution of carboplatin-impregnated 
calcium sulfate hemihydrate (C-I CSH) beads.  
Sample: Five immortalized cell lines from histologically confirmed, primary FISASs.  
Procedures: For each cell line, one 96-well microplate was used for each time point (24, 48, 72 
hours). In each microplate, 3 wells were seeded with ~7.5 x 103 cells per well for every 
carboplatin treatment added, ranging from 5 to 450 µM. Microculture plates were incubated for 
24, 48, or 72 hours. Drug efficacy was assessed via a bioreductive fluorometric assay. For 
apoptosis analysis, 3 wells were seeded with~5 x 104 cells per well for every carboplatin 
treatment added, ranging from 5 to 450 µM. Flow cytometry was performed and the relative 
percentages of viable, apoptotic, and late apoptotic/necrotic cells were reported. All experiments 
were run in triplicates.  
Results: Carboplatin exerted dose-dependent and time-dependent effects on FISAS cell viability. 
The IC50 values were within the range of carboplatin concentrations eluted from C-I CSH beads. 
Conclusion and Clinical Relevance: Elution of carboplatin from C-I CSH beads generate 
concentrations sufficient to result in 50% growth inhibition of FISAS cells in vitro. Local tumor 
control might be achieved by implantation of C-I CSH beads immediately following radical or 






Objective: To characterize spatial release of platinum from carboplatin-impregnated calcium 
sulfate hemihydrate (C-I CSH) beads using an agarose tissue phantom.  
Sample: 3-mm-diameter beads (n = 60) containing 4.6 mg carboplatin (2.4 mg platinum)/bead. 
Procedures: 18 L of 1% agarose were prepared and poured into 36 containers, each of which 
was 10 X 10 X 10 cm and filled half full (0.5 L/container). After the agarose solidified, 1, 3, 6, or 
10 C-I CSH beads were placed on the agar in defined patterns. An additional 36 blocks of agar 
(0.5 L/block) were placed atop the beads, positioning the beads in the center of 1 L of agar. The 
experiment was replicated 3 times for each bead pattern for 24, 48, and 72 hours, respectively. At 
these times, representative agarose blocks were sectioned in the x-, y-, and z-planes and labeled 
in accordance with their positions in shells radiating 1, 2, 3, 4, and 5 cm from the center of the 
blocks. Agarose from each shell was homogenized, and a sample was submitted for platinum 
analysis by use of inductively coupled plasma-mass spectroscopy. 
Results: Platinum diffused from C-I CSH beads at predicted anticancer cytotoxic concentrations 
for 2-5 cm radial source length.  
Conclusions and Clinical Relevance: Results of this study provided information regarding the 
spatial distribution of platinum expected to occur in vivo. Agarose may be used as a diffusion 
model, mimicking the characteristics of subcutaneous tissues. Measured platinum concentrations 






Objectives: To evaluate the pharmacokinetics and safety of carboplatin-impregnated calcium 
sulfate hemihydrate (C-I CSH) beads after implantation in healthy cats 
Sample: Six healthy adult research cats 
Procedure: Three C-I CSH beads were implanted into individual muscle pockets in specific 
patterns over both the right and left hemithoraces of all cats. Clinical laboratory testing was 
performed prior to the beginning of the study and at 3, 7, 14, and 21 days, and serum was 
analyzed for platinum content at specific times from 1 hour to 21 days. Tissue samples were 
obtained for histopathology and analysis of platinum at 3, 7, 14, and 21 days at specific distances 
from the sites of bead implantation. 
Results: At all time points and distances, tissue concentrations of platinum were sustained over 
21 days but below levels reported to be cytotoxic for FISAS cells in vitro. Serum concentrations 
of platinum increased to 3 hours and then decreased sharply, and mild abnormalities in serum 
calcium were noted. Some subcutaneous tissue samples were found to contain muscle which 
resulted in significantly higher platinum concentrations than in samples containing only 
subcutaneous fat. Minimal tissue changes were noted on histopathology. 
Conclusions and Clinical Significance: Implantation of C-I CSH beads was well-tolerated by 
healthy adult cats. C-I CSH beads implanted into muscle pockets did not release platinum into 
the subcutis at levels cytotoxic to FISAS cells in vitro. Use of muscle pockets should be 
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CHAPTER 1:  
LITERATURE REVIEW 
1.1 Platinum-based chemotherapeutics in veterinary patients 
The two most commonly used platinum based chemotherapeutics in veterinary medicine are 
cisplatin (cis-diamminedichloroplatinum II) and carboplatin (cis-diammine-1, 1-cyclobutane 
dicarboxylate platinum II).1-13 Platinum-based chemotherapeutics are thought to bind to cell 
DNA, thus interfering with transcription and DNA replication and inducing apoptosis.14,15 
Platinum drugs are also thought to bind to RNA, preventing reverse transcription, and 
cytoskeletal proteins, resulting in altered biologic functions.14,16-18  
 
In 1987, Knapp and others administered cisplatin systemically to healthy experimental cats and 
cats with oral squamous cell carcinoma. Cats that were administered cisplatin showed a dose-
related, primary pulmonary toxicosis, with or without saline diuresis.19 In 1988, Thamm and 
others administered a liposome-encapsulated cisplatin intravenously (IV) to 4 clinically normal 
cats every 3 weeks for 4 doses. This delivery method of cisplatin was found to be well tolerated 
by all cats with only a transient decrease in appetite, pyrexia, and elevated cholesterol noted in 
cats receiving this treatment.20 Fox et al. investigated the use of a second-generation lipophilic 
cisplatin analog, cis-bis-neodecanoato-trans-R,R-1,2diaminocyclohexane platinum (II), in 
healthy cats and cats with oral squamous cell carcinomas that failed to respond to conventional 
treatments or had nonresectable tumors.21,22 All healthy cats receiving the liposomal cisplatin 
analog experienced transient pyrexia, lethargy, vomiting, inappetence, and an acute species-
specific infusion reaction, but did not induce renal or pulmonary toxicosis.22 In cats with oral 
squamous cell carcinoma, the liposomal cisplatin analog was found to be ineffective at producing 
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a clinical response to treatment and resulted in an acute anaphylactoid-parasympathomimetic 
reaction, lethargy, inappetence, signs of depression, increases in hepatic enzyme activity, and 
melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Cisplatin has been 
shown to be a very effective chemotherapeutic drug in other species, but has shown toxicity to 
the kidneys and gastrointestinal tract.1-4 Subsequently, carboplatin, a second generation 
platinum-containing chemotherapeutic agent, was created to mitigate these toxic effects.23  
 
The recommended dosages for carboplatin use in cats are currently dictated by the systemic 
maximally tolerated dosage, body surface area, or glomerular filtration rate.24,25 To determine the 
prevalence and severity of carboplatin-induced dose-limiting toxicoses in the cat, Hahn et al. 
administered carboplatin as a single IV bolus ranging from 150-250 mg/m2 of body surface area. 
They found that a dose-limiting neutropenia and thrombocytopenia was significant for all cats 
administered a carboplatin dose at 200 or 250 mg/m2. Despite these hematologic changes, 
carboplatin appeared to be safe and clinically well tolerated in healthy cats when given as a 
single IV bolus. Fatal pulmonary toxicosis or nephrotoxicity was not observed in this study.26 
 
To determine the maximally tolerated dose and the dose limiting toxicosis of carboplatin in 
tumor-bearing cats, Kisseberth et al. conducted an open-label, dose escalation study, 
administering carboplatin to fifty-nine cats with measurable solid tumors.27 Based on this study, 
the dose of carboplatin recommended to treat tumor-bearing cats is 240 mg/m2 IV every 3–4 
weeks.27 In this study, there was no evidence of clinically relevant carboplatin-induced 
nephrotoxicity, respiratory signs consistent with pulmonary edema, or nonhematopoietic 
toxicosis. Carboplatin was safe and well tolerated by the cats in the study when administered 
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systemically. Although tumor regression was reportedly 11.9%, tumor response was only 
evaluated after a single dose and may be underestimating the effectiveness of the drug in tumor-
bearing cats, which warrants further investigation. 
 
1.2 Pharmacokinetic and safety profile of platinum-based chemotherapeutics  
One of the earliest attempts to characterize the pharmacokinetics of platinum chemotherapeutics 
involved IV administration of carboplatin and cisplatin to rodents. Both platinum compounds 
were excreted in the urine with 90% of carboplatin and ~45% of cisplatin being excreted within 
4 hours. The renal clearance of cisplatin was significantly greater than that of carboplatin 
suggesting that cisplatin was excreted by an active renal secretory mechanism while carboplatin 
was eliminated by glomerular filtration alone. This difference in excretion likely explains the 
lack of nephrotoxicity seen with carboplatin in comparison to cisplatin.28 
 
In 1998, Gaver et al. administered carboplatin IV to healthy beagles in doses ranging from 60-
580mg/m2. Plasma and urine samples were collected and analyzed for platinum content. The 
results of this study demonstrated that carboplatin is excreted in the urine and that carboplatin 
and plasma-free platinum exhibit a linear pharmacokinetic profile.29 
 
In 2004, Bailey and others characterized the pharmacokinetic disposition of carboplatin in 
tumor-bearing cats to determine whether glomerular filtration rate could be used to predict the 
clearance of carboplatin. A second objective of the study was to identify an association between 
glomerular filtration rate, platinum pharmacokinetics, and carboplatin-associated toxicities. All 
cats were treated with a dose of 200 mg/m2 of body surface area, yet the neutrophil concentration 
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nadir ranged from 200 to 8,000 cells/ml. They concluded that carboplatin-associated neutropenia 
was significantly correlated with the area under the concentration-versus-time curve for 
platinum, but the amount of drug received per unit of body surface area did not correlate.30 
 
In an attempt to make measurement of glomerular filtration more accessible, Bailey et al. also 
evaluated the use of serum iohexol clearance to predict plasma clearance of platinum in tumor-
bearing cats and to evaluate agreement between technetium and iohexol. A single dose of 
carboplatin was administered IV as a bolus, calculated by use of a target value for the area under 
the plasma platinum concentration-versus-time curve, and estimation of platinum clearance was 
derived from the glomerular filtration rate of technetium. This resulted in a median dosage of 
239.0 mg/m2. Results from this study revealed that in cats, serum iohexol clearance was an 
accurate predictor of platinum clearance and can be used to calculate carboplatin dose.31 
 
In 2009, Bailey and others used the carboplatin dose calculation derived from their previous 
study based on a targeted area under the concentration-versus-time curve and individual 
glomerular filtration rate to predict carboplatin-associated myelotoxicities. Cats received a single 
IV dose of carboplatin and were evaluated in cohorts of 3 cats each. If none of the cats developed 
a toxicosis, the dose was escalated 0.5 min•mg•mL−1 until the maximum tolerated dose was 
established. Neutropenia was the dose-limiting toxicosis. Other side effects included anorexia 
and thrombocytopenia. The median maximally tolerated dose of carboplatin was 227 mg/m2 
(range, 89-295 mg/m2). 31 
 




Novel drug delivery systems have allowed cancer treatments to result in fewer side effects and 
improve local tumor control, especially when used as an adjunctive treatment with surgery.32 
Chemotherapeutics are generally more efficacious when delivered directly to the diseased tissue 
at higher drug concentrations than can be attained with systemic administration.32 Due to the 
efficacy and widespread use of platinum-based chemotherapeutics in cancer treatment protocols, 
both cisplatin and carboplatin have been evaluated utilizing a variety of drug delivery systems.33  
 
Theon et al. published a series of studies reporting the use of intratumoral cisplatin in horses, 
dogs, and cats.12,34-37 Intratumoral injections of cisplatin in sesame oil were evaluated in equine 
sarcoids, squamous cell carcinomas, and other cutaneous neoplasms.35-37 Intratumoral injections 
were found to be safe and effective for use in equids. In another study by Theon and others, 
cisplatin was mixed with either sterile water or purified bovine collagen gel and administered 
into a variety of tumor types (fibrosarcomas, synovial sarcomas, and malignant melanomas) 
followed by radiation for a total of four treatments.34 In this study, the use of collagen in the 
formulation reduced clearance of the drug from the injection site as well as reduced systemic 
exposure to less than half the value observed after intratumoral administration of cisplatin mixed 
with sterile water. Plasma concentrations of platinum did not increase cumulatively in any dog 
during the course of the study. Theon et al. also evaluated intratumoral administration of 
100mg/m2 of carboplatin in a purified sesame oil emulsion to cats with squamous cell carcinoma 
of the nasal planum. Intratumoral carboplatin chemotherapy was found to result in minimal local 
toxicosis and was effective for cats with squamous cell carcinoma of the nasal planum without 
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cumulative effect seen after repeated administration. Complete clinical tumor clearance and 
complete response was observed in 67 and 73.3%, respectively.12 
 
Clearly, sustained delivery systems have the benefit of high tissue concentrations of a 
chemotherapeutic and decreased systemic side effects. Calcium sulfate hemihydrate is another 
delivery system that is biodegradable, inexpensive, causes minimal tissue reaction, and can be 
sterilized.38-43  
 
In a study performed by Marble et al., calcium sulfate hemihydrate beads containing cisplatin 
and calcium sulfate hemihydrate beads without cisplatin as controls were implanted into the 
cervical region of 6 healthy horses. All implantation sites of control beads exhibited swelling and 
edema around the bead, and implantation sites of cisplatin beads exhibited an inflammatory 
reaction that began immediately postoperatively that persisted until day 10 postoperatively. 
Edematous plaques developed in all horses with 2 horses developing alopecia and ulceration of 
the skin overlying the beads. Tissue samples obtained for platinum analysis revealed that 
platinum content in the tissues decreased as the distance from the bead increased. Histologic 
analysis revealed necrotizing cellulitis with mineralization and fibroplasia.44 
 
In 2006 Hewes et al. evaluated the use of cisplatin-containing calcium sulfate beads for treatment 
of naturally-occurring cutaneous neoplasms in equids. Horses with tumors <1.5cm were treated 
by implantation of beads alone, and for tumors >1cm, the tumors were resected or debulked prior 
to bead implantation. Tumors treated included sarcoids, fibrosarcoma, peripheral nerve sheath 
tumor, squamous cell carcinoma, melanoma, lymphosarcoma, adenocarcinoma, basal cell tumor, 
7 
 
and fibroma. Eighty-three percent of animals that were available for long-term follow-up were 
free of tumor recurrence 2 years after treatment and had minimal adverse effects. These results 
suggested that implantation of cisplatin-containing calcium sulfate beads may be effective at 
treating various cutaneous neoplasms in equids.45 
 
In 2016, Bergman and others investigated the use of cisplatin-impregnated calcium sulfate beads 
for treatment of cutaneous or subcutaneous soft tissue sarcomas in dogs following marginal 
tumor excision. In this study, cisplatin-impregnated beads were considered to be tolerated well 
with local toxicosis observed in 47% of patients. One of the dogs in the study had evidence of 
bone marrow suppression and sepsis suspected to be secondary to systemic absorption of 
cisplatin. Twenty-nine percent of cases had tumor recurrence. The median disease-free interval 
for dogs with grade 3 soft tissue sarcomas was 148 days, while a median disease-free interval 
was not reached for dogs with grade 1 and 2 tumors. These results suggested that marginal 
excision with adjuvant local chemotherapy delivered by intralesional placement of cisplatin- 
impregnated beads may be a reasonable treatment method for dogs with low- and intermediate-
grade soft tissue sarcomas.46  
 
Investigations of carboplatin-impregnated calcium sulfate hemihydrate beads have been sparse. 
Two case reports using the beads have been described.47,48 In the first case report, a 3-year-old 
male panther chameleon was diagnosed with multiple cutaneous squamous cell carcinoma 
lesions. Since surgical excision was not an option, a single bead was implanted into each of the 
lesions. Although not curative, there was significant regression of the lesions suggesting efficacy 
and potential use in reptiles. There were no adverse effects seen.47 In another case report, a 14.5-
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year-old spayed female domestic shorthair cat was evaluated for orbital lacrimal gland 
adenocarcinoma. Four weeks following initial diagnosis, the mass was excised and adjunctive 
cryotherapy was performed. Thirteen months postoperatively, the cat was represented for tumor 
regrowth. A second excision was performed with placement of carboplatin-impregnated beads. 
The cat remained free of recurrence at the time of writing of the publication, 11 months 
following the second surgery.48 Implantation of carboplatin-impregnated beads did not inhibit 
wound healing and may have contributed to the lack of recurrence. 
 
In a more recent study, Hess and others (2018) retrospectively evaluated the outcome of 
intralesional placement of carboplatin-impregnated calcium sulfate beads following surgical 
excision of subcutaneous soft tissue sarcomas in dogs. Furthermore, they prospectively evaluated 
the platinum content of 9 beads in 3 different manufacturer’s lots via spectrophotometry. Results 
revealed the calculated carboplatin content to be significantly greater than the labeled amount, 
and the total platinum content differed significantly among lots. Mild to moderate wound 
complications were observed following surgery and bead implantation in 38% of dogs. Thirty-
one percent of tumors recurred locally with a median time to recurrence of 84 days. Despite the 
manufacturing inconsistencies, the carboplatin-impregnated beads were well tolerated by the 
dogs in this study.49 
 
1.4 Feline injection site-associated sarcomas 
Feline injection site-associated sarcomas (FISAS) occur at sites of injections, and are thought to 
occur secondary to chronic inflammation with subsequent DNA damage and malignant 
transformation of cells. 50-55 FISAS are characterized by rapid growth and invasion into 
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surrounding tissues, with a high rate of local recurrence despite aggressive intervention. 56-62 
FISAS cells are distinct from spontaneously-arising fibrosarcomas in that they exhibit 
perivascular infiltration of lymphocytes and macrophages at the tumor periphery, a central area 
of necrosis, high mitotic index, severe cellular pleomorphism, and the presence of granulation 
tissue at the tumor periphery. 63,64 Recurrence of the tumor within 1-2 years is commonly 
reported despite multi-modal treatment approaches with wide or radical surgical excision, 
radiation therapy, and chemotherapy. 56-58,65 An effective role of systemic chemotherapy is 
debatable, with clinical trials having small numbers of cats and generally involving multi-modal 
treatment therapies.33,65-73 These studies involved the use of a variety of cytotoxic and cytostatic 
drugs with doxorubicin being the most widely investigated. Limitations with doxorubicin use in 
cats include its short half-life, as well as side effects such as myelosuppression and 
nephrotoxicity.65,66,68-70 These limitations warrant the investigation of other chemotherapeutics in 
cats with FISAS. 
 
A variety of chemotherapeutic drugs have been investigated for use against FISAS cells in 
culture.74,75 Lawrence et al. evaluated the use of a tyrosine kinase inhibitor, masitinib, against 
two feline injection site-associated sarcoma cell lines. This study demonstrated that masitinib 
significantly inhibited cell proliferation in a dose-dependent manner.74 In another study, 
doxorubicin, a cytotoxic anthracycline, and etoposide, a topoisomerase II inhibitor, were 
investigated alone and in combination on a single FISAS cell line.76 This study showed that both 
doxorubicin and etoposide, when used alone or in combination, had a significant growth 
inhibition and apoptotic effect on FISAS cells in culture. Williams et al. investigated the use of 
doxorubicin and mitoxantrone, and found that both anthracyclines had significant growth 
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inhibitory effects on FISAS cells in culture.77 Tubulin binding antimitotic agents, vincristine and 
paclitaxel, have also been evaluated in vitro against four FISAS cell lines.78 In this study, both 
vincristine and paclitaxel had significant dose-dependent effects on the viability of the FISAS 
cell lines. Although in vitro chemosensitivity assays cannot model in vivo factors such as tumor 
blood flow, drug metabolism, and the immune response, a strong correlation between  
 predictive assays and in vivo clinical responses has been reported, and can provide information 
regarding the potential efficacy of a given chemotherapeutic agent on cancer cells in culture.79   
 
1.5 Agarose phantom diffusion models 
In both human and veterinary medicine, attempts have been made to predict in vivo drug release 
from sustained-release drug formulations.80-84 Agarose is a linear polysaccharide that forms a 3-
dimensional porous structure containing mostly water.85 The polysaccharide molecules form 
double helices that aggregate to form fiber networks similar to the collagen matrix of the 
extracellular space with pore sizes similar to those encountered in physiologic soft tissues.80,86 A 
benefit of using agarose as a tissue phantom diffusion model of drug release is that it simulates 
the extracellular matrix conditions of subcutaneous tissues.80-82,87-89 
 
In a 2004 study, agarose gels of varying concentrations and porcine brain were tested to 
determine infusion characteristics. Magnetic resonance imaging and videomicroscopy were used 
to evaluate diffusion. Results showed that agarose gel at a concentration of 0.6% closely 




Most recently, in a 2017 study by Sidhu and others, a three-dimensional brain phantom to 
simulate brain biopsies was developed for training veterinary surgeons. Canine brain phantoms 
were fabricated from osteological skull specimens, 0.6% agarose gel (simulating brain 
parenchyma), and cheddar and mozzarella cheese molds (simulating meningiomas and gliomas). 
The phantoms developed in this study were cost- and time effective, and adequately simulated 
computed tomographic features of canine brains.90  
 
Leung and others developed a gel diffusion model to simulate the rate of drug release and 
diffusion from a subcutaneous injection using agarose gel as a tissue model. In this study, 
agarose concentrations of 1% were used to facilitate ease of dispensing and provide a qualitative 
in vitro model. This study demonstrated that a convenient in vitro release model consisting of 
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 IN VITRO CHEMOSENSITIVITY OF FELINE INJECTION SITE-ASSOCIATED 
SARCOMA CELL LINES TO CARBOPLATIN 
Introduction: 
Feline injection site-associated sarcoma (FISAS) has been attributed to the subcutaneous 
administration of vaccines and other injectable medications to cats, occurring in up to 1/ 1000 
vaccinated cats. 1,2 The household cat population has been estimated to exceed 66 million cats in 
the United States and over 40% of these cats receive at least 1 vaccine per year, creating a 
sizable population at risk. 1-4 Despite extensive research, the pathogenesis of FISAS has not been 
fully established. However, the most widely accepted theory implies a chronic inflammatory 
reaction at the site of an injection triggering subsequent malignant transformation of cells. 5-8 
FISAS cells have histological characteristics that are distinct from those of other spontaneously 
arising fibrosarcomas, such as perivascular infiltration of lymphocytes and macrophages at the 
periphery of the tumor, a central area of necrosis, high mitotic index, severe cellular 
pleomorphism, and granulation tissue at the periphery. 7,9 These tumors are very challenging to 
treat, as they grow rapidly and invade surrounding tissues. 3,6-12 Although distant metastasis 
affects 20%-28% of cats with FISAS, local recurrence of the tumor is the greatest cause of 
mortality, reported in 14%-45% of cats following complete excision and up to 70% of cats after 
incomplete excision of the tumor. 10-17 Radical surgical excision of the tumor offers the best 
prognosis, but often requires thoracic or abdominal wall excision, amputation, or 
hemipelvectomy, or removal of the scapula or dorsal spinous processes. 12 Although the addition 
of radiation therapy improves the prognosis, many cats may not receive radical surgery and 
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radiation therapy due to cost, invasiveness, or lack of access to a veterinary specialist. 14-17 
Unfortunately, most tumors recur within 1-2 years of treatment and are uniformly fatal. 11-17  
 
Carboplatin is a platinum-containing chemotherapeutic agent with similar anti-neoplastic 
efficacy than cisplatin, but less nephrotoxicity and emetogenicity. 18-22 Carboplatin has been 
evaluated for use in tumor-bearing cats and has shown some efficacy against FISAS, when given 
systemically. 19 The dose of carboplatin recommended to treat tumor-bearing cats is 240 mg/m2 
IV every 3-4 weeks. However, the recommended dosages for carboplatin are currently dictated 
by the systemic maximally tolerated dosage, body surface area, or glomerular filtration rate, 
rather than targeted tumor tissue concentrations. 22,23 Local administration of cisplatin and 
carboplatin has been studied as a strategy to decrease systemic toxicity. 24-29 Carboplatin-
impregnated CSH (C-I CSH) beads are a commercially available delivery system (Wedgewood 
Pharmacy, Swedesboro, New Jersey) developed for sustained release of carboplatin following 
implantation at sites of gross tumor or of marginal tumor extirpation. Preliminary studies have 
reported that platinum is released predictably from C-I CSH beads for 22-30 days. 30,31 Results 
from these studies provided estimations of the minimum and maximum platinum concentrations 
expected to elute from C-I CSH beads in vivo. 31 Calcium sulfate hemihydrate is a proven 
biodegradable carrier for drug release and causes minimal reaction in tissues. 32-42 However, 
before C-I CSH beads can be recommended for use in tumor bearing cats, the efficacy of C-I 





In vitro susceptibility testing of chemotherapeutics is a rapid way to determine the efficacy of a 
drug prior to administration. 43-46 Only 3 veterinary studies have evaluated the concentration of 
carboplatin that inhibits 50% of growth (IC50) of tumor cells in culture, including canine 
transitional cell carcinoma, melanoma, and mammary carcinoma cells. 44-46 To date, the 
concentration of carboplatin required to inhibit 50% growth of FISAS cells in vitro has not been 
determined. Although the in vitro chemosensitivity of other chemotherapeutic agents have been 
evaluated, none were evaluated in combination with a sustained-release local delivery system. In 
these studies, the ability of systemic administration to achieve therapeutic concentrations without 
toxicity in cats remained unclear. 47-49 
 
The first objective of the study was to evaluate the antiproliferative potency of carboplatin 
against FISAS cells by determining the 50% inhibitory concentration (IC50) and by apoptosis 
analysis. A second objective was to determine if IC50 values were within the range of 
concentrations eluted from commercially available C-I CSH beads. We hypothesized that the 
IC50s of carboplatin against FISAS cells measured at 24 and 72 hours post exposure would fall 
within the range of concentrations of carboplatin known to elute from C-ICSH beads. 30,31 
 
Materials and methods: 
Five immortalized cell lines (ELA-1, Hamilton, Kaiser, Teitz, and Rose) derived from 5 
histologically confirmed, primary FISAS tumors were generously provided (David Vail, 
University of Wisconsin). Cells were grown in continuous culture at 37oC, 5% carbon dioxide in 
complete Dulbecco’s modified of Eagle’s medium (Mediatech Inc, Manassas, Virginia) 
supplemented with 10% fetal bovine serum (Mediatech Inc, Herndon, Virginia), and 1% 
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penicillin streptomycin (Thermo Fisher Scientific Inc, Waltham, Massachusetts) in 100 x 20 mm 
sterile culture dishes (Falcon; Corning Inc, Corning, New York). Confluent cells were 
subcultured every 6-7 days using a standard trypsinization process. 
 
The effects of carboplatin on FISAS cell viability were assessed using a bioreductive 
fluorometric assay (Cell Titer Blue Cell Viability Assay; Promega Corporation, Madison, 
Wisconsin) according to instructions provided by the manufacturer. Immediately prior to 
initiating the study reported here, analyses of cell growth kinetics for all 5 cell lines were 
performed to determine the optimal concentration of cells that would maximize cell number 
without overcrowding wells or allowing the cells to outgrow their media before the 72-hour time 
point. Based on these analyses, 7.5 x 103 tumor cells were seeded per well and 3 wells were 
seeded for each carboplatin treatment using 96-well microplates (Falcon; Corning Inc). For cell 
culture experiments, a 96-well plate was prepared for each time point (24, 48, and 72 hours) and, 
additionally, 3 independent replicates of the entire experiment were performed. The wells were 
not randomized in order to minimize errors, a protocol consistent with previously published 
methods. 44-49 Microcultures were incubated for 24 hours prior to the addition of carboplatin to 
allow the cells to adhere. At time 0, culture media was removed and replaced with media 
containing a 0, 5, 25, 75, 150, 300, or 450 µM concentration of carboplatin. Cells in each 
microplate that were not exposed to carboplatin served as drug-free controls. At 24, 48, and 72 
hours following treatment, cells were assessed by the addition of an indicator dye (Cell Titer 
Blue Reagent, Promega Corporation) and use of a spectrophotometric microplate reader. Cell 
viability at each concentration of carboplatin was compared to that of control cells. IC50 values 
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for each cell line were defined as the concentrations of carboplatin that inhibited 50% of FISAS 
cellular metabolic activities. 
 
For flow cytometric analysis, 3 of the FISAS cell lines with the highest proliferative potential 
were chosen for evaluation —ELA-1, Hamilton, and Kaiser (Table 2.2). Approximately 5 x 104 
cells were plated per well and 3 wells were seeded for every carboplatin treatment using 6-well 
plates (Falcon; Corning Inc). A 6-well plate was prepared for each time point (24, 48, and 72 
hours) and, additionally, 3 independent replicates of the entire experiment were performed. 
Plates were incubated for 24 hours at 37oC. Following incubation at time 0, culture media was 
removed and replaced with media containing 0, 5, 25, 75, 150, 300, and 450 µM concentrations 
of carboplatin. At 24, 48, and 72 hours after the addition of the carboplatin, the supernatant was 
collected from each corresponding plate and transferred to 5 mL round-bottom polystyrene tubes 
(Falcon; Corning Inc). Adherent viable cells were then subjected to a standard trypsinization 
process and were also collected. FISAS cell suspensions were centrifuged at 1500 rpm for 5 
minutes. The supernatant was removed and the cell pellet was resuspended in 1.5 mL of Annexin 
V Binding Buffer (BD Biosciences, San Jose, California). Control and treated cells were stained 
using the Annexin V FITC Apoptosis Detection Kit (BD Biosciences) and analyzed with a flow 
cytometer (BD LSR II, BD Biosciences). Data were acquired using BD FAC Suite software (BD 
Biosciences) and using the Annexin V FITC assay. Data were derived and were analyzed using a 
minimum of 50,000 cell events for every carboplatin treatment (0-450 µM), and the software 
automatically generated a report. FSC-A versus SSC-A plots were used for gating cells and to 
identify alterations in scatter properties of the cells. Annexin V FITC-A versus Propidium Iodide 
(PI)-A plots from the gated cells identified cell populations corresponding to viable cells 
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(Annexin V–/PI–), early apoptotic cells (Annexin V+/PI–), and late apoptotic/necrotic cells 
(Annexin V+/PI+), and results were reported as relative percentages. Mean values from the 3 
independent replicates of the entire experiments are reported. 
 
Statistical analysis:  
The sample size selected for cell culture is based on alpha = 0.05, power = 0.80, an expected 
difference in apoptosis of 100 cells between the highest and lowest carboplatin concentrations, 
and a standard deviation of 50 cells for each group. IC50 values were computed for inhibitory 
dose response data using a nonlinear variable slope model procedure preprogrammed in Graph 
Pad Prism 7 (GraphPad Software, Inc, La Jolla, California). Measured response values (R) for 
each cell line and replicate were independently normalized using Y = min R/(max R–min R). 
Dose concentrations were log10-transformed (X). The nonlinear Hill Slope and IC50 were 
estimated for each cell line and replicate using the relationship: The Hill Slope describes the 
steepness of the curve, where a slope of -1.0 is standard and more negative values are steeper. A 
linear mixed model was used to evaluate the results for cell viability assays and apoptosis over 
time, with dose, cell line, and replicate as fixed factors and individual culture as a random 
variable. SAS 9.4 (SAS Institute, Cary, North Carolina) was used to analyze the data. 
Continuous data were evaluated for fit to a Gaussian distribution using the Shapiro-Wilk test, 
skewness, kurtosis, and q-q plots. Non-normally distributed data were log transformed for 





Carboplatin induced both dose-dependent and time-dependent decreases in the viability of 
FISAS cells (Figure 2.1). After 24 hours, IC50 mean values for each cell line ranged from 37.8 to 
106.8 µM (overall mean IC50 68.3 µM, median IC50 89.9 µM). After 48 hours, IC50 mean values 
for each cell line ranged from 66.8 to 145.3 µM (overall mean IC50 98.1 µM, median IC50 94.0 
µM). After 72 hours, mean IC50 values for each cell line ranged from 21.3 to 46.3 µM (overall 
mean 34.1 µM, median IC50 36.9 µM) (Table 2.1). Although cell susceptibility to carboplatin 
generally increased over time when comparing the 24-hour IC50 values to the 72-hour IC50 
values, increases in the IC50 values at the 48-hour time points were noted for cell lines 2-4. The 
IC50 values for all 5 cell lines at all time points were within the range of carboplatin eluted from 
C-I CSH beads in preliminary studies. 30,31 Flow cytometric analysis of treated and untreated 
cells from 3 cell lines confirmed a dose-dependent effect of carboplatin on apoptosis of FISAS 
cells. Figure 2.2 shows a representative dose-response plot with Annexin V FITC-A versus PI-A. 
In the untreated control sample, the majority (90.7%) of cells were viable and nonapoptotic. 
Treatment with increasing concentrations of carboplatin resulted in decreases in viable cells 
(Annexin V–/PI–) and increases in cells undergoing early apoptosis (Annexin V+/PI– cells) and 




Treatment with carboplatin resulted in both dose-dependent and time-dependent decreases in cell 
viability of cultured FISAS cells. In carboplatin-treated wells, the proportion of nonviable cells 
was substantially increased 72 hours after exposure to carboplatin compared to control wells. In 
a preliminary evaluation of in vitro elution of C-I CSH beads from the same manufacturer 
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(Wedgewood Pharmacy), 2 sampling methods were employed to mimic different wound 
environments. Method 1 involved complete exchange of eluent at every time point to simulate a 
wound environment with rapid and complete extracellular fluid exchange. This method would 
determine the minimum concentration of carboplatin that would be expected to occur in vivo. 
Method 2 involved no exchange of eluent, thereby simulating a wound environment with 
negligible fluid exchange. This method would evaluate the cumulative release of carboplatin into 
the surrounding medium over time and the maximum concentration of carboplatin that would be 
expected to occur in vivo. 
 
Because wounds or tumor beds will vary among dogs and cats in size, vascularity, severity of 
inflammation, and rate and proportion of wound fluid exchange, it was concluded that the actual 
concentration of carboplatin eluted in vivo from C-I CSH beads should fall within the range of 
the reported minimum and maximum in vitro concentrations (Figure 2.3). 31 Inhibitory 
concentration 50% values in the present study were within the range of carboplatin 
concentrations shown to elute from C-I CSH beads in the preliminary study, indicating that 
carboplatin elutes sufficiently from C-I CSH beads to result in 50% growth inhibition of FISAS 
cells in culture. Mean concentrations of carboplatin eluted per bead at 24 and 72 hours in the 
preliminary study were 4 and 80 times the maximum 24- and 72-hour IC50 values for carboplatin 
obtained in the present study against any FISAS cell line. These data indicate implantation of 





Cisplatin and carboplatin delivery systems based on substrates such as open-cell polylactic acid 
(OPLA-Pt), hyaluronic acid, and others have been found effective against canine appendicular 
osteosarcoma, nasal tumors, and soft tissue sarcomas. 20,25-29,32 However, these substrates are not 
commercially available, have shown unacceptable local toxicity such as wound dehiscence and 
infection, or have resulted in equivocal clinical improvement. In contrast, CSH beads are 
biocompatible and biodegradable, with minimal local reactivity and rare to no systemic toxicity. 
28,29,38-40 Based on previous studies and results of the present study, implantation of C-I CSH 
beads may improve survival by delivering high concentrations of carboplatin directly to the site 
of greatest need, the extirpated tumor bed.  
 
In vivo efficacy of a local chemotherapy delivery system depends not only on the concentration 
of chemotherapy released, but also on diffusion of the agent in tissues. The spatial distribution of 
carboplatin released from C-I CSH beads in a tissue has not been reported. The manufacturer 
suggests that beads be implanted every 2 cm within a wound bed, but this recommendation is not 
substantiated by experimental data. 24 Although our results suggest that implantation of one bead 
every 2 cm in a wound bed would result in greater than 50% inhibition of FISAS cells, further 
studies are needed to characterize the 3-dimensional diffusion of carboplatin from C-I CSH 
beads implanted in vivo. Limitations of our in vitro study include the exposure times of 24, 48, 
and 72 hours, which do not necessarily correspond to the duration during which carboplatin 
concentrations may be maintained locally in vivo. Additional factors including tumor blood flow, 
drug metabolism, and the host and tumor immune responses may alter concentrations and 
efficacy of a chemotherapeutic agent. Therefore, a direct comparison of results of this in vitro 
study to in vivo situations is not possible. However, a good correlation has been documented in 
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man between in vivo clinical responses and in vitro predictive assays. 50 These studies compared 
the in vitro chemosensitivity of tumor cells with tumor response after systemic administration of 
a chemotherapeutic agent. Although more significant in vitro-in vivo correlation may be 
expected with local administration of a chemotherapeutic agent such as C-I CSH beads, in vivo 
studies are needed to verify this hypothesis.  
 
The IC50s of cell lines 2-4 (Hamilton, Kaiser, and Teitz) were higher at 48 hours than at 24 and 
72 hours, an unexpected finding as cultured tumor cells generally become more susceptible to 
chemotherapy with time. 44,45,47 This finding may have resulted from abnormalities in the cell 
culture environment, exponential overgrowth of cells within the incubation period, or technical 
error. Although an analysis of cell growth kinetics was performed for each cell line prior to the 
start of this experiment to optimize the number of cells to be evaluated, this analysis does not 
account for a potential increase in proliferation of viable cells as other cells begin to die. As cells 
became confluent during the 24-hour period, growth may have slowed or stopped; as more cells 
underwent apoptosis at 48 hours, the remaining viable cells continued to grow, resulting in a 
higher IC50 value at that time point compared to the 24-hour time point. Furthermore, one study 
reported that certain cell line-specific responses characterize more aggressive neoplastic 
phenotypes and potential resistance to chemotherapy. 48 Finally, although the FISAS cell lines 
evaluated in the present study were historically established, repeated passages may affect clonal 
expansion and influence our results. Immortal cells can be passaged frequently, however, 
without affecting their growth cycles and characteristics with careful maintenance. 51 One study 
detected no difference in spontaneous proliferation rate between 2 FISAS cell lines across 




In conclusion, administration of carboplatin had significant dose- and time-dependent inhibitory 
effects on the viability of FISAS cells in culture and induced apoptosis in a majority of cells by 
72 hours. The IC50 of each FISAS cell line was within the reported range of elution of C-I CSH 
beads. 31 Local tumor control may therefore be achieved by implantation of as few as one C-I 
CSH bead immediately after radical excision of the primary tumor. Additionally, recurrent 
tumors may be treated minimally invasively by simple implantation of beads without tumor 
resection, or by marginal excision of larger tumors with concurrent bead implantation. Although 
these results show promise for the use of C-I CSH beads in cats with FISAS, further studies are 











Figures and Tables: 
Figure 2.1:  
Carboplatin induced both dose-dependent and time-dependent decreases in the viability of 







Figure 2.2:  
Representative Annexin V FITC-A versus Propidium Iodide-A contour plots from untreated cells 









Figure 2.3:  




















Table 2.1:  
Mean IC50 values for all cell lines after 24 hours and 72 hours of incubation 
 
 
                                         IC50  
Cell lines 24 hours 72 hours 
Cell Line 1 (ELA-1) 89.9 µM 39.3 µM 
Cell Line 2 (Hamilton) 56.3 µM 26.8 µM 
Cell Line 3 (Kaiser) 51.2 µM 36.9 µM 
Cell Line 4 (Teitz) 37.8 µM 46.3 µM 
























Table 2.2:  
 
For flow cytometric analysis, 3 of the feline injection site-associated sarcoma cell lines with the 




aMean values for percent viable and apoptotic/necrotic cells for 3 cell lines at 24 hours and 72 
hours after treatment with 450 µM carboplatin are shown. 
 
Carboplatin 
450 µM  
               
               24 hours 
                         
              72 hours 
 % Viable  % Apoptotic/necrotic  % Viable  % Apoptotic/necrotic  
Kaiser 48.07 51.55 7.64 92.24 
ELA-1 83.16 16.10 7.7 92.31 
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SIMULATION OF SPATIAL PLATINUM DIFFUSION FROM CARBOPLATIN-
IMPREGNATED CALCIUM SULFATE HEMIHYDRATE BEADS USING AN 
AGAROSE GELATIN TISSUE PHANTOM MODEL 
Introduction: 
Local, sustained-release chemotherapeutic delivery systems have been developed to decrease the 
incidence of systemic toxic effects of chemotherapeutic agents while achieving high 
concentrations at tumor sites and optimizing local control of nonresectable and incompletely or 
marginally resected tumors. 1-10 Localized administration of cisplatin and carboplatin has been 
evaluated, and cisplatin and carboplatin sustained-release delivery systems have shown efficacy 
against canine appendicular osteosarcoma, nasal tumors, and soft tissue sarcomas.4,5,7,8,11-16 
However, these delivery systems are not commercially available, have unacceptable local toxic 
effects (eg, wound dehiscence and infection), or have resulted in equivocal clinical improvement.  
Given these limitations, there remains a clinical need for the development and validation of 
localized drug delivery strategies for improving the management of certain cancers in companion 
animals.   
 
Carboplatin-impregnated calcium sulfate hemihydrate (C-I CSH) beads are a commercially   
available delivery systema for sustained release of carboplatin and are intended for implantation   
at sites of gross tumor or of marginal tumor extirpation. Calcium sulfate hemihydrate is a proven   
depot for drug release and is biodegradable, biocompatible, inexpensive, and able to be   
sterilized.10,12,17-23 Several uncontrolled, clinical case series have demonstrated   
promise regarding the efficacy of cisplatin- and carboplatin-impregnated CSH beads against   
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various tumors in horses, dogs, and other species.12,24-26 Antitumor effects were observed in  
these animals without clinically significant local or systemic toxicity, but studies characterizing 
the elution rate and pattern of platinum release from C-I CSH beads were previously lacking.    
To address this informational void, in two controlled, experimental, in vitro studies, our   
laboratory demonstrated that platinum elutes from C-I CSH beads for 22-30 days in   
concentrations significantly higher than those achieved with systemic administration of 
carboplatin.23,24 Additionally, the authors and others have shown that the concentration of   
platinum released from C-I CSH beads sufficiently achieves anticancer cytotoxic concentrations   
against various neoplasms, including feline injection site-associated sarcomas (FISAS).27-30   
Despite these important in vitro findings supporting the potential clinical utility of C-I CSH,   
additional sophisticated modeling systems are required to more faithfully recapitulate true drug  
release kinetic profiles of C-I CSH within the localized tumor microenvironment.31-33 
 
Different strategies have been employed to predict in vivo drug release from sustained-release   
drug formulations.34,35 Following subcutaneous or intramuscular injection or implantation in   
mammals, administered medications encounter an extracellular matrix that behaves more like gel  
than bulk fluid.36-39 Hydrogels have therefore been proposed as tissue models for local drug   
diffusion owing to mechanical properties similar to those of the extracellular matrix comprising   
the subcutaneous and muscular tissues.32,40    
 
Agarose is a hydrogel consisting of a linear polysaccharide material and has a variety of   
scientific applications. At relatively low concentrations in aqueous solution, agarose solidifies to   
form a gel at room temperature. Solidified agarose gel forms a three-dimensional structure with   
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pore sizes similar to those encountered in physiological tissue.41-43 Agarose phantoms also mimic 
several other mechanical properties of mammalian tissue crucial for understanding drug   
diffusion such as volume of distribution, density, and permeability.44-46 As a result, agarose gels 
provide realistic conditions for characterizing diffusion of drugs administered via subcutaneous 
or muscular routes and are a proven surrogate to mammalian tissue. Agarose tissue phantoms 
have been studied most extensively in neuropharmacology where concentrations of agarose from 
0.6% to 2% have shown similar infusion pressure profiles to mammalian brain.45-50 A 
concentration of 0.6% to 1% was found to most closely mimic characteristics of mammalian soft 
tissues.46,51-53  
 
An in vivo investigation of cisplatin-impregnated beads placed subcutaneously in horses with  
dermal or subcutaneous neoplasms showed that cisplatin diffused to a radial distance of   
approximately 1.5 cm from the site of implantation, and platinum concentrations gradually   
decreased as distance from the bead increased.54 Based on the findings of this study, the   
manufacturers of cisplatin- and carboplatin-impregnated beads recommend the beads be spaced 2   
cm apart when implanted in clinical animals. However, to the authors’ knowledge, no controlled   
studies evaluating the diffusion characteristics of C-I CSH beads have been published to   
substantiate this recommendation, nor has the spatial release of platinum from C-I CSH beads 
been determined for small animals.  
 
The primary objective of this study was to characterize the spatial release of platinum from  
C-I CSH beads using an agarose gel tissue phantom diffusion model. A secondary goal was to 
generate translationally relevant data that could be used to guide development of the optimal 
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pattern or pattern(s) for C-I CSH bead implantation to be used in tumor-bearing companion 
animals, including cats with injection site–associated sarcomas. 
 
Materials and methods: 
Carboplatin impregnated-calcium sulfate hemihydrate beadsb were created at an accredited 
compounding pharmacy.c Briefly, a forged metal bead moldd was used to create 3-mm-diameter 
beads. Each of the C-I CSH beads contained 4.6 mg of carboplatin (2.4 mg of platinum), 18.4 mg 
of calcium sulfate hemihydrate, and a retardant.e  
 
Thirty-six liters of 1% agarose gel were prepared; each liter of the gel was created by adding 1 L 
of distilled water to 10 g of agarose powder.f The resulting slurry was heated to boiling and 
stirred by use of a rotary hot plate until the agarose powder was completely dissolved. The 
aqueous 1% agarose solution was allowed to cool slightly for 5 minutes. Then 500 mL of the 
solution was poured into each of 36 plastic containers; each container was 10 X 10 X 10 cm and 
was filled only half full. The 0.5-L blocks of agarose gel were allowed to cool to room 
temperature (20-25°C) and solidify. Once each gel had solidified, 1, 3, 6, or 10 C-I CSH beads 
were placed on the surface of the 36 agar blocks in 4 defined patterns (Figure 3.1). Because the 
manufacturer of C-I CSH beadsc recommended that the beads be placed 2-cm apart when 
implanted in tissue, the 4 defined patterns were created by symmetrical placement of the beads 
spaced 2-cm apart in all directions. When only 1 bead was evaluated, it was placed centrally 
within an agar gel block. When 3, 6, or 10 beads were evaluated, they were placed as centrally as 
possible within an agar block while maintaining a distance of 2 cm between beads. Thirty-six 
additional 0.5-L blocks of agarose gel were created. These were placed atop the other 36 blocks 
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and beads, effectively positioning the beads within the center of a 1-L agar block (Figure 3.2). 
Blocks and beads were maintained at room temperature. The experiment was replicated 3 times 
for each of the 4 bead patterns for time periods of 24, 48, and 72 hours, respectively. At  
these times, representative agarose blocks were sectioned into 1 cm slabs in the x, y, and z planes  
and labeled according to their positions in shells radiating 1, 2, 3, 4 and 5 cm from the center of  
the blocks. (Figure 3.3). All beads were removed from the agar.  
 
Agarose from each shell was homogenized and a sample submitted for platinum analysis by 
inductively coupled plasma-mass spectroscopy (ICP-MS). Homogenization of the agar slabs 
comprising each shell served to minimize the effects of gravity on the measured spatial 
distribution of platinum.  An additional sample was obtained from each shell for the replicates at 
24, 48, and 72 hours and analyzed as a quality control measure. These additional samples were 
evaluated for platinum content and compared with content of the original samples from each 
shell to determine whether there were any differences in platinum concentration. This 
comparison served as an evaluation of the complete homogenization of each shell and a 
confirmation that the original samples were representative. 
 
Statistical Analysis: 
 A 1-compartment model for theophyllineg was adapted by adding a code for clearance, 
absorption rate, and elimination rate. Estimates for some pharmacokinetic parameters (eg, 
clearance, absorption rate, and elimination rate) from the basic 1-compartment 
model were verified by use of a pharmacokinetic statistical programh. The full parameterization 
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of the 1-compartment model was used to analyze multivariate interactions among the 
experimental variables. Values were considered significant at P < 0.05. 
  
Results: 
The C-I CSH beads released platinum predictably in the agarose tissue phantom (Table 3.1). 
There were no significant differences in platinum concentrations among replicates and between 
the original samples and the quality control samples, which indicated a high degree of precision 
in preparation of all agarose gels, sectioning of gels, homogenization of the agarose comprising 
individual shells, and performing the platinum analysis. At all time points, platinum 
concentration decreased in each individual shell as the distance of the shell from the C-I CSH 
bead or beads increased (Figure 3.4). Comparison within shells over time (24, 48, and 72 hours) 
revealed that there was an overall decrease in the platinum concentration in the innermost shells 
and an increase in platinum in the outermost shells over time (Figure 3.5). Evaluation of results 
for 1 bead at 24 hours revealed that the platinum concentration was highest in shell 1 (within 1 
cm of the centrally positioned bead; 128 mg/L) and decreased precipitously in shell 2 (1 to 2 cm 
from the centrally positioned bead; 27 mg/L). The addition of more beads to the agar blocks 
resulted in an increase in platinum concentrations in all shells. Figure 3.6A and Figure 3.6B 
show diffusion of platinum into each of 5 shells at 24 (A) and 72 (B) hours after implantation of 
C-I CSH beads into the agarose gels. A range of the estimates of pharmacokinetic parameters 
determined by use of a 1-compartment model for platinum concentrations measured 24, 48, and 
72 hours after implantation of 1, 3, 6, and 10 C-I CSH beads in agarose gels is summarized in 





To mimic the subcutaneous tissue environment, the release of platinum from C-I CSH beads into 
an agarose gel tissue phantom was measured under static conditions as a function of time and 
space. Mechanisms that may affect drug transport in in vitro situations include migration, 
convection and diffusion.32 For the conditions of the present study, the mass transport of 
platinum in the surrounding environment was affected mainly by diffusion, which is a critical 
transport process in subcutaneous tissues. Diffusion is a mass transfer phenomenon  
that causes the distribution of a chemical species to become more uniform in space as time  
passes.31,32,50 At all time points, concentrations of platinum diminished with increasing distance 
from the center of the bead pattern and agar block. Evaluation of all bead configurations revealed 
that concentrations were highest within 1 to 2 cm of the center of the block (shells 1 and 2) and 
diminished substantially in shells 4 and 5 located 4 to 5 cm from the center of the block. 
 
Exposure time also had a substantial effect on platinum release from the beads. Interestingly, the 
platinum concentrations increased with increasing exposure time in the outer shells (shells 4 and 
5) and diminished with increasing exposure time in the inner shells (shells 1 and 2). This 
phenomenon was evident for all bead patterns and indicated that platinum was not continuously 
released from the beads over the entire 72-hour period. At some time < 72 hours, platinum 
release from the beads likely ceased or substantially slowed, and the platinum began moving 
from shells 1 and 2 toward shells 4 and 5. This observation may be akin to the burst phenomenon 
observed in classical elution studies, wherein an initial burst of drug release occurs in the first 24 
hours of elution, followed by a sharp decline in release thereafter.22,23,55-59 With regard to 
localized carboplatin treatment for susceptible tumors, this observation indicated that the greatest 
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impact on tumor cell death may be expected to occur in the first 24 to 72 hours after 
implantation. 
 
An unexpected finding was that platinum concentrations obtained after 48 and 72 hours were  
substantially less than those obtained after 24 hours. If accumulation of platinum were to occur  
over each additional time period, it would be expected that 48-hour accumulations would be  
greater than 24-hour accumulations, and 72-hour accumulations greater than those measured at  
48 hours. Given platinum was observed to move from the inner to the outer shells over time, and  
that the concentrations of platinum in the outermost shell 5 were not zero, platinum may have  
been lost to analysis by diffusion beyond 5 cm and out of the agar block altogether. Agar blocks  
were contained within 10 x 10 x 10 cm plastic containers. Upon sample collection, a mild to  
moderate amount of aqueous solution was noted in the interface between the agar block and the  
walls of the container.  It is possible that platinum that diffused out of the agar block was  
concentrated in this aqueous solution. The aqueous solution was not evaluated for platinum  
content. However, the solution may mimic a “sink” effect seen physiologically wherein drug  
diffused into the subcutaneous space is carried away by the vascular and lymphatic 
circulations.31-33  
 
Few strategies have been used  in human and veterinary medicine to predict in vivo drug release 
from sustained-release drug formulations.31-35 The most frequently utilized in vitro methods 
evaluate elution, or release of a drug into a bulk fluid reservoir, often with agitation.22,31,32,55 Bulk 
fluids utilized most commonly include phosphate buffered saline and serum or plasma. Examples 
of reservoirs include vials, beakers, or dialysis bags, and sample withdrawal was performed most 
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often by complete exchange of the bulk fluid eluent at predetermined time points.22,23,31,32,55 Bulk 
solution concentrations were then measured as a function of time. The net effect of complete 
exchange of eluent medium and agitation is to assure that a steep concentration gradient is 
maintained between the surface of the bead and the surrounding bulk fluid at all times. Such an 
effect does not reliably simulate the conditions beads are likely exposed to in in vivo situations, 
where wounds or tumor beds vary among dogs and cats in size, vascularity, severity of 
inflammation, and rate and proportion of wound fluid exchange. As an initial response to this 
concern, two different bulk fluid sampling methods to characterize elution of platinum from C-I 
CSH beads, one that involved complete eluent exchange at every time point, and one that 
involved no eluent exchange. It was concluded that the resultant concentrations represented the 
minimum and maximum range of platinum release possible from C-I CSH beads, and suggested 
the actual platinum release in vivo should fall between the minimal and maximal concentrations 
reported. Interestingly, the present study showed that release of platinum from C-I CSH beads 
into an agarose medium for 24 and 72 hours generated concentrations within the range of the 
previously reported minimum and maximum values, as was suggested would occur in an actual 
wound or tumor bed.24   
 
A purported benefit of the agarose tissue phantom as a diffusion model of drug release is that it  
more accurately simulates the extracellular matrix and release conditions of tissues in a live 
animal.31-33,50,60,61 Agarose is a linear polysaccharide that forms a 3-D porous structure 
containing mostly water but that has measured pore sizes similar to those encountered in 
physiologic soft tissues.31-33,36 Cooling the polysaccharide molecules results in formation of 
double helices that aggregate to form fiber networks similar to the collagen matrix of the 
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extracellular space.39 Agarose hydrogels, although simplistic, have been widely validated as in 
vitro methods that can be used to predict the in vivo behavior of various drug formulations.31-
33,43,46  
 
Inhibitory concentration 50% (IC50), or the concentration of carboplatin necessary to achieve  
50% inhibition of replication of tumor cells or tumor cell death in vitro, has been used to assess 
efficacy of carboplatin in human and veterinary studies.27,62,63 Previous studies reported the IC50s 
of tumors including canine transitional cell carcinoma, melanoma, and mammary carcinoma at 
72 hours to be 1.2, 1.2, and 16.9 mg platinum/L, respectively.27-29 Recently, the authors showed 
carboplatin to have a significant dose- and time-dependent inhibitory effect on the viability of 
FISAS cells in culture and induced apoptosis in a majority of cells by 72 hours.30 The overall 
mean IC50 of carboplatin for 5 FISAS cell lines was found to be 13.2 mg platinum/L at 24 hours 
and 6.6 mg platinum/L at 72 hours.  
 
An objective of the present study was to derive the ideal pattern of bead implantation for local 
treatment of FISAS. The data presented here indicate that by 24 hours, one C-I CSH bead 
released platinum for a distance of 2 cm at concentrations greater than the IC50 for FISAS. The 
addition of beads to totals of 3, 6 and 10 C-I CSH beads extended effective diffusion only to a 
distance of 3 cm from the center of the bead pattern and agar block. By 72 hours, one C-I CSH 
bead also released platinum for a distance of 2 cm at concentrations greater than the IC50 for 
FISAS. However, by 72 hours, the addition of beads to totals of 3, 6 and 10 beads extended the 
sphere of effective diffusion to distances 3, 4 and 5 cm from the center of the bead patterns and 
agar blocks, respectively. This finding indicates that for tumors or extirpated tumor beds with 
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radii of 3, 4 and 5 cm, implantation of 3, 6, and 10 beads in the chosen patterns, respectively, 
should provide diffusion of platinum sufficient to result in 50% inhibition of tumor cell growth 
or cell death over the entire affected area. For tumors with radii <2 cm, local tumor control may 
be achieved by implantation of as few as one C-I CSH bead immediately following excision of 
the primary tumor. Additionally, recurrent tumors may be treated minimally invasively by simple 
implantation of beads without tumor resection, or by marginal excision of larger tumors with 
concurrent bead implantation.  
 
Limitations of the present study included the nature of the agarose gel. In studies conducted by 
our research group, hydrogels consisting of an agarose concentration of 1% have been used to 
mimic the diffusion characteristics of subcutaneous tissues. In the present study, markings (1-cm 
grid) were imprinted on the agar blocks to improve the precision for sectioning of shells; 
however, the semisolid agar occasionally collapsed during sectioning, and some blocks were 
softer than others. Although agarose powder was precisely measured by use of a gram scale and 
distilled water was collected in 1-L beakers, water may have been lost to evaporation during 
boiling in some cases, which would have changed the consistency of the agar among blocks. 
Although no significant differences were detected in the measured platinum concentrations, such 
inconsistencies could have affected the platinum concentrations. Also, to minimize effects of 
gravity on the measured spatial distribution of platinum, agar comprising each shell was 
homogenized and processed collectively, and a representative sample was obtained from each 
homogenized shell for analysis. However, as the number of the shell increased, the volume of 
agarose gel increased, and this may have impacted our ability to completely homogenize the 




Ideally, in vitro model systems are tested at physiologic temperature and pH. Given the large  
physical scale of the experimental set-up, maintenance of the agar blocks at body temperature  
was not possible. Agar was made with distilled water at pH 7.0 as previously described.31-
33,43,47,50 However, the use of phosphate buffered saline pH 7.4 as a solvent for the agarose 
powder may permit testing at physiologically relevant pH.  
 
Finally, exposure times of 24, 48, and 72 hours do not necessarily correspond to the time period 
that carboplatin concentrations might be maintained locally in vivo. Additional factors including 
tumor blood flow, lymphatic drainage, drug metabolism, and the host and tumor immune 
responses may alter concentrations and efficacy of any chemotherapeutic agent.   
 
For the study reported here, platinum was released from C-I CSH beads into agarose as a 
function of 3-dimensional space and time and offer recommendations for patterns of bead 
implantation relative to tumor bed size. However, the in vivo fate of platinum diffused from C-I 
CSH beads is expected to be more complex than modeled here, involving metabolism, cellular 
uptake, and degradation.31 Although widely validated as a model of drug diffusion, agarose gel is 
a simplistic, inert, non-perfused medium and cannot mimic the entire complexity of actual in 
vivo conditions.43,50 In small animals with tumors, growth and excision of the neoplasm is 
expected to result in loss of tissue organization and aberrant behavior of cellular components and  
extracellular tissues of the subcutaneous space. Further studies are necessary to determine 
whether platinum release into an in vitro agarose tissue phantom is predictive of in vivo release 
and to affirm dosing recommendations for beads used in clinical settings. 
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Figures and tables: 
Figure 3.1: 
Schematic of the bead pattern (top row) and photograph of agar gels with implanted C-I CSH 















A 500 mL agar block without beads was placed, inverted, atop a 500 mL agar block with beads, 
effectively positioning the beads within the center of a 1-L block. Note the centimeter cross 

















Schematic depiction of the 3-D shells (shells 1 to 5) that were spaced 1-cm apart and radiated 
from the center of each 10 X 10 X 10-cm agar block. The entire agar comprising each shell was 











Figure 3.4:  
Platinum concentration as a function of bead number in shells 1-5 over time.  At each time point, 
platinum concentrations were highest in shell 1 (1 cm) and lowest in shell 5 (5 cm). Note that 


















Platinum concentrations as a function of time in shells 1-5 according to bead number. Note that 









Diffusion of platinum at 24 and 72 hours by shell. At 24 and 72 hours, one C-I CSH bead 
released platinum for a distance of 2 cm, at concentrations greater than the IC50 for FISAS. At 24 
hours (A), the addition of beads to totals of 3, 6 and 10 C-I CSH beads extended effective 
















By 72 hours (B), the addition of beads to totals of 3, 6 and 10 beads extended the sphere of 

















Table 3.1  
Mean ± SD platinum concentration measured in each of 5 shells at various times after 
implantation of 1, 3, 6, and 10 C-I CSH beads in agarose gels.  
    Platinum concentration (mg/L)    
Time (h) Shell 1 bead  3 beads  6 beads  10 beads   
24 5 < 0.100 ± 0 0.178 ± 0.03 1.153 ± 0.10 1.633 ± 0.41 
4 0.182 ± 0.08 1.876 ± 0.51 7.133 ± 1.65 11.800 ± 0.46 
3 2.470 ± 0.85 9.607 ± 1.50 27.670 ± 2.99 41.430 ± 4.88 
2 27.030 ± 12.57 43.970 ± 12.55 101.200 ± 26.85 117.400 ± 46.94 
1 128.300 ± 25.42 167.300 ± 55.94 187.700 ± 7.77 196.700 ± 49.52 
Total 158.1  222.9  324.9  369.0 
 
48 5 0.895 ± 1.26 0.930 ± 0.20 3.127 ± 0.25 6.330 ± 1.13 
4 1.810 ± 0.81 4.010 ± 1.02 11.100 ± 1.65 20.400 ± 2.17   
 3 3.397 ± 1.58 14.400 ± 1.80 26.000 ± 4.92 45.270 ± 6.11 
2 12.480 ± 6.02 36.900 ± 6.08 55.800 ± 7.36 90.500 ± 11.99 
1 36.270 ± 24.64 66.170 ± 22.10 96.500 ± 9.17 100.400 ± 27.89 
Total 54.85  122.4  192.5  262.9 
 
72 
5 0.382 ± 0.04 1.697 ± 0.43*† 4.240 ± 0.36*† 9.677 ± 0.38*†‡ 
4 1.243 ± 0.12*† 4.810 ± 0.64*† 10.120 ± 0.23*†‡ 17.700 ± 1.71*†‡§ 
3 4.073 ± 0.72*† 10.560 ± 1.07*†‡ 19.100 ± 2.10*†‡§ 43.300 ± 5.74*†‡§ 
2 8.897 ± 3.12*†‡ 21.330 ± 3.76*†‡§ 48.500 ± 4.40*†‡§ 64.070 ± 12.83*†‡§ 
1 32.300 ± 26.6*†‡§ 50.530 ± 7.02*†‡§ 79.400 ± 13.02*†‡§ 95.370 ± 74.88*†‡§ 
Total 46.90  88.93  161.4  230.1 
 
Shells 1 to 5 radiated 1, 2, 3, 4, and 5 cm from the center of each 1-L block, respectively. 
*Platinum concentrations measured in the present study are expected to be effective against 
transitional cell carcinoma of dogs.28 †Platinum concentrations measured in the present study are 
expected to be effective against melanoma of dogs.28 ‡Platinum concentrations measured in the 
present study are expected to be effective against injection site–associated sarcoma of cats.27 
§Platinum concentrations measured in the present study are expected to be effective against 




 Range of the estimates of pharmacokinetic parameters clearance, Ka (absorption rate constant) 
and Ke (elimination rate constant) by diffusion time (h) and number of beads (2.4 mg Pt/bead). 
Estimates for these pharmacokinetic parameters were determined by use of a 1-compartment 
model for platinum concentrations measured at various times after implantation of 1, 3, 6, and 10 
C-I CSH beads in agarose gels and verified in WinNonlin 5.0.h 
Time (h) No. of beads Clearance (L/kg/cm) Ka (h-1)  Ke* (h-1) 
24 1  0.0075–0.0119  2.409–4.475 NA 
 3  0.0183–0.0370  1.841–2.775 NA 
 6  0.0335–0.0395  1.121–1.636 NA 
 10  0.0424–0.0740  1.029–1.105 NA 
 All  NA   NA  1.593 
 
48 1  0.0158–0.0559  1.636–13.132  
 3  0.0431–0.0646  1.252–2.263 NA  
 6  0.0505–0.0696   1.335–1.522 NA 
 10  0.0765–0.0817  0.720–1.250 NA 
 All  NA   NA  1.000 
 
72 1  0.0344–0.0640  1.116–2.404 NA  
3  0.0335–0.0666      1.064–2.482         NA 
6  0.0558–0.0773  0.885–1.322 NA 
10  0.0643–0.1247  0.490–1.111 NA 
All  NA   NA  1.335 
 
*Value reported is the mean.  
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PHARMACOKINETIC AND SAFETY EVALUATION OF CARBOPLATIN-
IMPREGNATED CALCIUM SULFATE HEMIHYDRATE BEADS AFTER 
IMPLANTATION IN HEALTHY CATS 
Introduction: 
Feline injection site-associated sarcomas (FISAS) occur at sites of injections and are thought to 
occur secondary to chronic inflammation and subsequent malignant transformation of cells. 1-6 
Feline injection site-associated sarcomas are characterized by rapid growth and invasion into 
surrounding tissues, with a high rate of local recurrence despite aggressive intervention. 7-13 
FISAS are distinct from spontaneously-arising fibrosarcomas in that they exhibit perivascular 
infiltration of lymphocytes and macrophages at the tumor periphery, a central area of necrosis, 
high mitotic index, severe cellular pleomorphism, and the presence of granulation tissue at the 
tumor periphery. 14,15 Recurrence of the tumor within 1-2 years is commonly reported despite 
multi-modal treatment with wide or radical surgical excision, radiation, and chemotherapy. 7-9,16 
Local, sustained-release chemotherapeutic delivery systems have been developed to enhance 
regional control of locally aggressive tumors while decreasing systemic toxicity associated with 
chemotherapeutic agents. 17-23 Platinum-based sustained-release delivery systems have been 
investigated for treatment of canine appendicular osteosarcoma, nasal tumors, and soft tissue 
sarcomas. 17,20,21,24-26 However, these delivery systems are not commercially available or have 
resulted in local toxicosis such as erythema, swelling, wound dehiscence, and tissue necrosis. 
Calcium sulfate hemihydrate is a proven biodegradable and biocompatible carrier for sustained 
drug release. 27-30 Carboplatin-impregnated calcium sulfate hemihydrate (C-I CSH) beads are a 
commercially availablea delivery system intended for implantation at sites of gross tumor or of 
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marginal tumor extirpation. Carboplatin has been evaluated systemically in tumor-bearing cats, 
and showed evidence of antitumor activity with no drug-induced nephrotoxicosis or pulmonary 
edema. 31 Although carboplatin appears to be safe and well tolerated when given IV to cats as a 
single bolus, treatment protocols are based on the maximally tolerated dose and not targeted 
tissue concentrations.  In vitro elution studies have shown that platinum is released predictably 
from C-I CSH beads for 22-30 days,32 at concentrations exceeding the dose required to inhibit 
growth of 50% (IC50) of a variety of canine cancer cells in vitro.
32-34 Results from this study 
provided estimations of the minimum and maximum platinum concentrations expected to elute 
from the beads in vivo. In another study, the IC50s of FISAS cells in culture were found to be 
within the reported range of platinum expected to elute from the beads. 35 We also performed 
studies to characterize the spatial release of platinum from C-I CSH beads using an agarose gel 
tissue phantom diffusion model. 36 Results showed that platinum diffused from C-I CSH beads at 
anticancer cytotoxic concentrations for 2-5 cm radial source length. If these concentrations are 
mirrored in the in vivo situation, there may be a potential clinical utility of the beads as a local 
chemotherapeutic delivery device. To date, however, no studies exist evaluating the 
pharmacokinetic and safety profiles of C-I CSH beads in cats. The objective of this study was to 
characterize the pharmacokinetic profile and evaluate the safety of C-I CSH beads after 
implantation in healthy cats. 
 
Methods and Material:  
Materials 
All carboplatin-impregnated beadsa evaluated in this study were created at an accredited 
compounding pharmacyb. Briefly, a forged metal, polytetrafluoroethylene-coated bead moldc 
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was used to create 3-mm-diameter beads containing 4.6 mg carboplatin (2.4 mg platinum) and 
18.4 mg calcium sulfate hemihydrate per bead with an added retardantd. Control beads were 
formed containing 23.0 mg calcium sulfate hemihydrate and an added retardantd.  
Experimental animals 
Six adult research cats (Cats 1-6) weighing 3.2-5 kg [7.0-11.0 lb] (mean 3.7kg [8.1lb]) were 
housed in standard, individual cages in a temperature-controlled environment with alternating 
12-hour cycles of light and dark. Cats were permitted to acclimate to the environment for 14 
days prior to the study and fed standard feline dry food and water ad libitum throughout the 
acclimation and study periods. Two cats were obtained from a reputable commercial cattery and 
4 cats were transferred from another research protocol. Three of the cats transferred from another 
protocol had vascular access ports in place within a jugular vein. All surgical procedures were 
performed by a board-certified veterinary surgeon (HP) under the guidance of laboratory animal 
veterinarians and according to the Guide for the Care and Use of Laboratory Animals 8th 
Editione. 
Anesthesia and aseptic preparation 
Cats were pre-medicated with dexmedetomidine 0.008 mg/kg and ketamine 2 mg/kg 
intramuscularly [IM]. Cats received a single dose of long-acting buprenorphine (SIMBADOL, 
Zoetis Inc. Kalamazoo, MI) 0.24 mg/kg subcutaneously [SC] following pre-medication and 
another dose one day postoperatively. A cephalic catheter was placed aseptically and all cats 
were induced with propofol 4 mg/kg IV to effect and maintained with isoflurane in 100% oxygen 
following intubation. Perioperative monitoring included continuous ECG and indirect blood 
pressure monitoring, pulse oximetry, end-tidal carbon dioxide, and assessment of anesthetic 
depth, heart rate, respiratory rate, and temperature every 5 minutes. Lactated Ringer’s solution 
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was administered at 5 ml/kg/h during the anesthetic period. A 14x14cm2 area of skin centered on 
each lateral hemithorax and a small area over the dorsal lumbar region were clipped of hair and 
aseptically prepared. Clinical laboratory testing including a complete blood count and serum 
biochemistry panel was performed prior to beginning the study and on days 3, 7, 14, and 21.  
General health evaluation included recording of food and water consumption, elimination, 
activity level, and subjective clinical observations of attitude, level of consciousness, and 
hydration. 
Bead implantation 
A 10x10cm2 diagram (Figure 4.1A) of 5 concentric circles increasing in radii by 1 cm and 3, 3-
mm blue circles spaced centrally 2 cm apart was designed and printed. The 3-mm blue circles 
designated the sites of bead implantation, and the concentric circles permitted accurate 
determination of biopsy sites central to the beads and at 1, 2, and 3 cm from the beads. Two 
black X’s were marked on the diagram to designate sites of sham suture placement. Holes were 
punched over the blue circles and black X’s, and the transparency was sterilized, creating a 
template for use in surgery. The templates were placed over the clipped areas of the skin of each 
cat’s left and right hemithoraces, and a mark was placed on the skin using a sterile marker for 
each of the proposed bead implantation sites (Figure 4.1B). Using the templates as guides, 3 C-I 
CSH beads were implanted bilaterally in the same pattern in each cat in individual muscle 
pockets (Figure 4.1C). A small, 1.0 cm incision was made in the skin over each proposed 
implantation site with a #15 scalpel blade. Small metzenbaum scissors were used to carefully 
dissect the subcutis to the cutaneous trunci muscle. Each bead was positioned over the muscle 
and sutured into a small pocket of muscle by placement of a single subcutaneous cross-mattress 
suture of 4-0 poliglecaprone-25. Two additional small incisions were made for placement of 2 
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sham sutures of 4-0 poliglecaprone-25. These suture sites served as controls in histopathological 
studies. Additionally, a single control bead without carboplatin was implanted SC in the dorsal 
lumbar region in each cat. Each incision was closed with a single, buried cruciate suture of 4-0 
poliglecaprone-25 in the subcutis and a single cruciate suture of 4-0 nylon in the skin. Thoracic 
incision sites were covered with stockinette and the cats were recovered from anesthesia. Cats 
were monitored postoperatively by assessment of heart rate, respiratory rate and temperature and 
by regular assessment for signs of discomfort. Cats were permitted ad libitum food and water on 
recovery from anesthesia. 
Pharmacokinetic and Safety Assessment 
Whole blood samples were drawn either directly from a jugular vein or from a vascular access 
port at 1, 2, 3, 6, 12, and 24 hours, and at 2, 3, 7, 14, and 21 days. The samples were centrifuged 
and serum and plasma separated. The samples were stored frozen at approximately −70◦C. 
Serum samples were analyzed for platinum content by inductively coupled plasma-mass 
spectrometry (limit of detection: 0.1 parts per million)f. A complete blood count (CBC) and 
serum biochemical panel were performed prior to the study and at 3, 7, 14, and 21 days post-
operatively. Hematologic and renal toxic effects were graded in accordance with the VCOG 
Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v 1.0.14. 37  
The pharmacokinetic (PK) parameters were evaluated by a 1-compartment with extravascular 
input model, C(t)=A(e-ket - e-kat), where C(t) is the measured platinum concentration at time t, ka 
and ka are the elimination (a.k.a. k10) and absorption (a.k.a. k01)  rate constants. A is a macro 
constant defined as Dka /V/( ka - ka), where D is the dose and V is the volume of distribution. By 
trial, we determined the best weight function was w = 1/ , where  is the estimated platinum 
concentration. Initial estimates of PK parameters were obtained for each distance for the data 
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from all cats. Estimates for A, ka and ke were starting values to model the PK for each 
cat/distance combination. Starting values were adjusted by trial to obtain the best values for 
diagnostics (R2, AIC), and plausible estimates of Cmax, Tmax, clearance (Cl), and half-life (t1/2).  
Analyses of variance of these PK parameters and area under the curve (AUC) were carried out to 
determine differences between distances.  Cat 1 was excluded from the analysis because mean 
platinum concentrations increased between day 14 and 21, while all other cats showed a decrease 
in mean platinum concentrations. 
Tissue sampling 
Tissue samples were taken for histopathology and analysis for platinum content at 3, 7, 14, and 
21 days. A sterile 10x10cm2 grid template with 5 concentric circles increasing in radii by 1cm 
was placed over the clipped areas of the skin of each cat’s thorax and a mark placed on the skin 
using a sterile marker, for each proposed biopsy site. The sampling sites were at sites central to 
the beads and along concentric circles 1, 2, and 3 cm from the sites of bead implantation (Figure 
4.2). On day 3, samples were obtained from the left thorax of each cat in a specified pattern. On 
day 7, samples were obtained from the right thorax of each cat in the same pattern. On days 14 
and 21, samples were obtained as for days 3 and 7, but in a pattern rotated 120 degrees from the 
first pattern. Cats were pre-medicated, anesthetized, and aseptically prepared as described for 
bead implantation. A 6-mm biopsy punch was used to obtain 4 biopsy samples of tissue from the 
areas surrounding bead implantation and one biopsy from a sham suture site. One biopsy sample 
was also obtained from the dorsal lumbar control site of each cat on day 7. Each tissue sample 
was halved to permit both histopathological evaluation and evaluation for platinum content. 
Biopsies were routinely processed, paraffin embedded, sectioned at 7µm, and stained with 
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hematoxylin and eosin. Each section was evaluated and scored under light microscopy by a 
board-certified veterinary pathologist (MV) unaware of the biopsy sites. 
Average epidermal thickness was determined by measuring the thickness of the epidermis at 5 
random locations, in microns, then adding them and dividing by 5. Inflammation scores within 
the dermis and subcutis were subjectively scored on a scale of 0-4 with 0 representing no 
discernable inflammation and 4 representing marked inflammation.  Fibrosis scores were 
similarly scored subjectively on a scale of 0-4 with 0 representing no fibrosis and 4 representing 
marked fibrosis. A necrosis score was also subjectively evaluated within the subcutis on a scale 




Implantation of C-I CSH beads was well tolerated by all cats. There were no major changes in 
overall general health noted in any of the cats. Within each cat, results of the CBCs and serum 
biochemical analyses obtained at 3, 7, 14, and 21 days did not differ substantially from values 
obtained prior to implantation. All cats were moderately anemic (grade 2) throughout the course 
of the study compared to baseline, with Cat 5 having a grade 4 anemia on day 3, which improved 
with each subsequent blood sample and no intervention; median hematocrit [HCT] 23%, range 
11-29.7% [reference range 30-45%]. All cats had grade 2-3 elevations in creatine phosphokinase 
[CPK], median 853.75 U/L, range 255-2000 U/L [reference range 10-250 U/L] throughout the 
study period (Figure 4.3). All cats had abnormalities in serum calcium [Ca] levels with mild 
(grade 1) decreases in calcium in two cats and mild to moderate elevations in calcium (grades 1-
2) in four cats (Figure 4.4), median Ca 10.7 mg/dL, range 8.3-13.7 mg/dL) [reference range 8.8-
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10.2 mg/dL]. All cats had elevations in phosphorus [Ph] (grade 1), median 5.07 mg/dL, range 4.0 
- 6.4 mg/dL [reference range 3.2-5.3 mg/dL]; Two cats had mild elevations in creatinine on 
baseline biochemical evaluation (1.7 and 1.8 mg/dL [reference range 0.4-1.6 mg/dL]), but these 
values remained within the reference range throughout the course of the study. One cat (Cat 3) 
was noted to have a mild increase in creatinine (grade 1) on days 7 (1.9 mg/dL [reference range 
0.4-1.6 mg/dL]), day 14 (1.7 mg/dL), and day 21 (2.1 mg/dL), and in another cat (Cat 4) on day 
14 (1.7 mg/dL). A urine analysis obtained via cystocentesis of Cat 3 between days 7 and 14 
revealed a urine specific gravity of 1.033, and protein 1+ and rare hyaline casts, supportive of 
dehydration. Cats 3 and 4 were anorexic intermittently throughout the study period but willing to 
accept canned cat food when offered, and exhibited decreased water intake. Subcutaneous fluids 
were administered to Cat 3 between day 7 and 14, 14 and 21, and at the end of the study period 
and Cat 4 also received subcutaneous fluids between days 14 and 21. There were no other 
concerns regarding intake or elimination. Clinical laboratory analyses were not performed after 
the conclusion of the study, but all cats were reported to be clinically well at the time of writing 
of this report. All cats in the study experienced mild-to-moderate swelling and bruising of the 
skin and mild hemorrhage in the subcutis at the surgical sites postoperatively that was self-
limiting. All incisions healed without complication.   
Pharmacokinetic Results  
Pharmacokinetic variables are shown in Table 1. Plots of serum platinum concentration versus 
time are shown in Figure 4.5. Serum concentrations peaked at 2.9mg/kg platinum (55.19 mg/m2 
of calculated carboplatin) 3 hours postimplantation (PI) and dropped to 0.59 mg/kg platinum 
11.23 mg/m2 of calculated carboplatin) by 12 hours. By day 14, platinum levels were below 
detectable ranges (limit of detection: 0.1 parts per million).  
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Based on the PK modeling, mean tissue platinum concentrations, depicted in Figure 4.6, were 
highest on day 5 at the central biopsy site (3.35 mg/kg of platinum; 63.75 mg/m2 of calculated 
carboplatin). Between days 14 and 21, mean concentrations of platinum in all cats and from all 
sites were maintained at a concentration of 1.0 mg/kg of platinum (19.0 mg/m2 of calculated 
carboplatin), with the highest concentrations found centrally and 1 cm from the beads at both 
time points. Mean tissue concentrations of platinum for each biopsy site decreased as the 
distance from the beads increased. All cats had platinum detected from the sample site adjacent 
to the control bead with a mean concentration of 0.79 mg/kg ± 0.29mg/kg of platinum (15.0 
mg/m2 of calculated carboplatin). Due to minimal subcutaneous fat available for biopsy in some 
locations and the division of samples for platinum analysis and histopathology, 16 samples 
obtained for platinum analysis contained muscle. Platinum concentrations in samples with 
muscle were significantly higher than concentrations in samples containing only subcutaneous 
fat (2.58 mg/kg platinum ± 1.68 mg/kg; 49.0 mg/m2 of calculated carboplatin). 
Gross and Histopathologic Evaluation 
Macroscopically there was mild-to-moderate swelling at the site of bead implantation 
postoperatively, and both swelling and bruising were noted at various biopsy sites 
postoperatively on days 3, 7, 14, and 21. Some areas of firm swelling were located in close 
approximation to subsequently planned biopsy sites, and were grossly and histologically 
determined at subsequent biopsy times to be hematomas.  
Inflammation in tissue sections was mild-to-moderate and predominated by neutrophils and 
macrophages. Inflammation was located in the subcutaneous adipose tissue around the 
subcuticular skeletal muscle. Inflammation scores were highest on days 14 and 21 PI and in 
sections from the sham suture site, the central biopsy site, and the site of control bead 
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implantation. Multinucleated giant cells were often seen surrounding suture material or necrotic 
adipocytes within the subcutis and were noted in sections taken at 7, 14, or 21 days PI. 
Subcutaneous necrosis was noted most often in sections from the control site, sham site, or 
central biopsy site, and most often at 7, 14, or 21 days PI. Sections with necrosis also commonly 
contained segments of suture material and more pronounced inflammation scores. Macrophages 
surrounding necrotic adipocytes tended to be epithelioid and foamy. In some sections, 
macrophages contained small amounts of amphophilic to gold-tinged pigment in the cytoplasm. 
Cats 1, 3, and 6, also had small numbers of eosinophils in the subcutis. Eosinophils were noted 
most often on days 7 and 14 PI in the sham suture sample or in the central biopsy sample. 
Fibrosis within the subcutis was also often associated with suture material within the section. 
Sections with the highest fibrosis scores were from the sham suture site, central biopsy site, and 
the site of control bead implantation. Mild fibrosis scores were assigned to sections from sites 1, 
2, and 3 cm from the beads. No significant changes were noted in hair follicles.  
 
Discussion: 
Local, sustained-release administration of carboplatin offers the potential to maintain high 
concentrations of drug over time at the site of disease.17-23,38 This study revealed that C-I CSH 
beads slowly released carboplatin into surrounding tissues over 21 days. Two to three hours PI, a 
peak was observed in the serum platinum concentration-time curves. This is likely related to the 
‘burst effect’ commonly seen with slow release drug delivery systems in addition to immediate 
uptake of the drug into system circulation.39 This occurs due to surface drug dissolution followed 
by erosion degradation of the matrix and a slow rate of drug release.39-41 As supported by our 
previous work using an agar tissue phantom, 36 distances further from the beads showed 
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increases in concentrations with increased exposure time indicative of radial movement of 
released platinum in the medium; this movement of platinum substantially slowed after day 7. 
Platinum levels were not evaluated beyond day 21 in the serum or tissues. Although there was 
detectable drug at day 21 in the tissues, this amount was below cytotoxic concentrations reported 
in vitro for canine and feline cancer cells.34,35,42-46 
 
The dose of carboplatin recommended to treat tumor-bearing cats is 200-240 mg/m2 IV every 3–
4 weeks.31,47 A mean peak plasma platinum concentration of 23 +/- 7 mg/L was reported after 
administration of a single IV dose of 200 mg/m2 carboplatin in the cat.48 In the present study, 
systemic absorption of platinum after implantation of 6 C-I CSH beads was minimal with an 
average peak serum concentration of 3 mg/kg (57.09 mg/m2 of calculated carboplatin), well 
below that achieved with the recommended IV dose.  
 
Elution of drug into tissues from substrates for sustained-release is dependent on hydrostatic and 
colloid osmotic pressures of the capillaries and interstitium.49-51 In patients with normal 
interstitial fluid dynamics, complete exchange of extracellular fluid may occur frequently, often 
within hours.49,52 Therefore it is not surprising that in our study, platinum concentrations within 
the tissues were low, and serum platinum peaked by 3 hours PI. In a study characterizing the 
elution of platinum from C-I CSH beads in vitro, platinum was measured using a sample 
collection method that closely mimicked an in vivo environment with rapid, complete fluid 
exchange.32 With this sampling method, platinum concentrations dropped significantly by 48 
hours and by day 3 were almost undetectable. In the present study, platinum levels were highest 
at the sampling site central to all 3 beads on day 3 and at sites central to and 2 cm from the beads 
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on day 7. This suggests that most of the platinum was released within the first week, with mean 
peak platinum concentrations diffusing to a radial distance of 2 cm by day 7, and maintaining 
low concentrations within the tissues at all distances for up to 21 days PI. 
 
Carboplatin concentrations reported to be inhibitory to 50% (IC50) of FISAS cells in culture at 24 
hours were 13.4 mg/L (134 mg/m2), and at 72 hours, 6.7 mg/L (67 mg/m2).35 In the present 
study, mean peak platinum tissue concentrations at 72 hours were below the reported mean IC50 
for FISAS cells at 72 hours. Although measurement of tissue concentrations of platinum in the 
present study in excess of the IC50 for FISAS cells would have been ideal, tumor cell lines 
cultured in laboratory settings have been shown to be of a more aggressive neoplastic phenotype 
as well as demonstrate resistance to chemotherapy. 44,53 Therefore, calculated IC50s may be in 
excess of what is required in an in vivo setting, and lower concentrations of carboplatin may be 
effective in tumor-bearing cats. Carboplatin-impregnated CSH beads may be effective at 
controlling local disease even at lower tissue platinum concentrations because the tumor 
environment, regional blood supply, and local and systemic immunologic processes can affect 
the deposition, delivery, and effectiveness of the drug.54 Furthermore, solid tumors have 
increased interstitial fluid pressures due to increased vascular permeability, changes in lymphatic 
flow, and inflammatory infiltrates.55-57 Although changes in tumor microenvironment can lead to 
inefficient uptake of systemically-administered chemotherapeutic agents in the presence of gross 
tumor,57,58 increased interstitial fluid pressures may allow for sequestration of chemotherapeutic 
agents locally when C-I CSH beads are implanted, increasing the local concentrations and 
efficacy. Carboplatin-impregnated CSH beads may therefore be useful for use in non-resectable 
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or following incomplete tumor resection with residual microscopic disease at the surgery site. 
Further evaluation is needed to investigate efficacy in a controlled clinical trial setting. 
 
Sixteen biopsy specimens had the addition of muscle sampled, and these samples were 
statistically significantly higher than concentrations with subcutaneous fat, likely due to bead 
placement in a muscle pocket and an increased acute inflammatory response that resulted in 
sequestration of the chemotherapeutic within the muscle tissue. Placement of beads in muscle 
pockets has been recommended to control the distribution of beads and chemotherapeutic agent 
in a wound or tumor bed, and to prevent pooling of implanted beads in gravity dependent areas. 
However, based on our findings, the use of muscle pockets to secure the beads should be 
reconsidered for C-I CSH bead placement in animals with dermal or subcutaneous tumors, as 
concentrations in the affected tissues may not be maximized nor reach therapeutic levels. Secure 
placement of beads in subcutaneous fat might be achieved by use of a mattress suture around the 
bead that stabilizes the bead within the fatty tissue, permitting release of drug directly into the 
site of greatest need. 
 
Mean tissue concentrations for each biopsy site showed decreases in concentrations of platinum 
as distance from the beads increased. Based on mean platinum concentrations detected at each 
distance, bead placement closer than 2 cm apart may need to be investigated in order to maintain 
cytotoxic concentrations at the wound bed. Several individual biopsy samples that contained 
muscle did reach cytotoxic concentrations, but given that a majority of the samples only 
contained subcutaneous tissues, this does not truly reflect the concentrations able to be achieved 
at the would bed. Unexpectedly, a small amount of platinum was found near the control bead site 
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on day 7 in all biopsy samples. With the exception of the control bead biopsy site, tissue samples 
for platinum analysis were not obtained beyond 3cm from the C-I CSH beads. However, mean 
concentrations of platinum 3 cm from the C-I CSH beads were > zero, indicating platinum 
diffusion likely exceeded 3 cm and may have contaminated the tissues surrounding the control 
bead.36 Mean platinum concentrations obtained from the control biopsy site exceeding 3cm were  
slightly lower than concentrations obtained from the 3cm biopsy sites, consistent with the radial 
diffusion pattern observed from the beads, where there are decreasing concentrations of platinum 
with increasing distances from the beads.  
 
Based upon the labeled content of 2.4 mg platinum/bead, each cat should have received a total 
dose of 14.4 mg of platinum (3.9 mg/kg of platinum; 74.2 mg/m2 of calculated carboplatin). In a 
recent study, platinum content in C-I CSH beads were found to be variable, with a mean 
platinum content of 5.4 mg per bead.59 Taking this into consideration, each cat could have 
received a total dose of 32.4 mg of platinum (8.8 mg/kg of platinum; 167.5 mg/m2 of calculated 
carboplatin). Although there was minimal systemic uptake of platinum from the beads, this 
amount may be altered depending on the physical environment of the wound or tumor  
bed. In order to avoid exceeding the recommended IV doses of 200-240 mg/m2, a 
recommendation of no more than 11-13 mg/kg of platinum (21-25 mg/kg of carboplatin) should 
be implanted using C-I CSH beads assuming the maximum dose of platinum could be absorbed 
systemically. In vitro elution studies evaluating C-I CSH beads however, have shown a 





Significant adverse effects were not observed in any cat, however abnormalities in serum 
calcium were noted in all cats. Based on its calcium content, calcium sulfate has been reportedly 
used to fill bone defects, as a bone graft expander, for treatment of nonunion, and for antibiotic 
delivery.61,62 Transient moderate to severe hypercalcemia has been reported following 
implantation of antibiotic-impregnated calcium sulfate beads in revision arthroplasty in people, 
with elevation in calcium noted by day 2-3 PI, peaking between days 5-7, and returning to 
normal by day 10.63,64 Transient mild hypercalcemia has also been reported in two studies using 
an alloplastic calcium sulfate implant to fill bone defects in dogs.65,66 However, in another study 
evaluating calcium sulfate in cortical defects of the femurs of dogs, serum total calcium 
remained within the reference range throughout the study period.67 The United States Food and 
Drug Administration recommends caution when considering implantation of resorbable calcium 
salts in patients with pre-existing hypercalcemia.68 The present study is the first to report 
hypercalcemia in cats following implantation of a calcium sulfate compound. Although no cats 
showed any significant clinical signs associated with calcium derangement, Cats 3 and 4 did 
display episodes of anorexia which could have been secondary to hypercalcemia (range 10.7-
13.1 mg/dL). Pre- and postoperative serum levels of calcium should be evaluated with 
implantation of calcium sulfate hemihydrate beads in small animals. Platinum-related systemic 
toxicosis such as pulmonary edema and nephrotoxicity were not observed in this study, however 
urine analysis was not performed concurrently.69-71 Observed hematologic and biochemical 
changes such as anemia and elevations a CPK and phosphorus were likely related to frequent 
blood sampling and stress associated with handling and administration of intramuscular 
injections. Mild elevations in creatinine in two cats were attributed to dehydration, however renal 
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injury secondary to carboplatin administration, although unlikely, cannot be completely ruled 
out. 
 
Minimal tissue changes were noted on histopathology, and were likely attributable to tissue 
trauma associated with surgical biopsy and reaction to the suture, rather than a foreign body 
reaction (FBR) to the beads. Reported characteristics of normal surgical biopsy sites include 
nondegenerate neutrophils, monocytes, eosinophils, and fibrosis.72,73 Foreign body giant cell 
(FBGC) formation is considered a hallmark of the FBRs and was only seen around sites with 
suture in the present study. Bruising and swelling of the skin and subcutis at surgical sites were 
attributed to hemorrhage from the surgical procedure, as electrosurgical hemostasis was not 
utilized, bleeding was noted to be minimal during procedures, and bleeding was responsive to 
mild and brief tamponade. Bruising, swelling, and hematoma formation were self-limiting and 
did not interfere with healing, but may have affected degradation of CSH beads and absorption 
and measurement of platinum.  
 
One limitation of the present study is the use of a muscle pocket to secure the beads as 
recommended by the manufacturer. Biopsy samples containing muscle had higher concentrations 
of measured platinum predominantly at 7 days and again at 21 days; these were days when 
samples most commonly included muscle tissue. Based on findings of this study, it is likely 
placement of beads within a muscle pocket would have a negative effect on the overall local 
efficacy of carboplatin in the treatment of dermal or subcutaneous tumors. Ideally, an equal 
distribution of muscle and subcutaneous fat would have been obtained from each biopsy site, 
however sampling was limited by the overall thin body condition of the cats. One publication 
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detailing the use of cisplatin beads recommends folding the beads into an absorbable hemostatic 
sponge to secure the beads into deeper tissues74, however this would likely affect the diffusion of 
the drug and has not been investigated. Alternative methods to secure the beads in the tissue 
should be considered and investigated. Additionally, more frequent or earlier tissue sampling 
may have allowed for detection of higher concentrations of platinum. Urinalysis was only 
performed on one cat with persistently elevated creatinine. Baseline and weekly assessments of 
renal function using urinalysis in all cats would have been ideal given that platinum agents may 
be nephrotoxic. However, urine collection was limited by laboratory animal housing provisions 
and the fractious nature of the cats, as several cats urinated during the pre-medication process 
despite efforts to reduce stress. None of the cats in the study exhibited any signs of clinically 
relevant nephrotoxicity. 
 
In conclusion, implantation of C-I CSH beads was well tolerated by healthy adult cats with mild 
elevations in calcium and minimal histopathologic changes. At all time points and distances, 
tissue concentrations of platinum were sustained and measurable over 21 days. Low levels of 
platinum were detected in serum throughout the study period. Use of muscle pockets should be 
reevaluated for C-I CSH bead placement in animals with dermal or subcutaneous tumors. Local 
tumor control may still be achieved by implantation of C-I CSH beads in cats with FISAS. 
Although tissue levels of platinum in this study were below the target cytotoxic concentrations 
for FISAS reported in vitro35, further studies are needed to evaluate the diffusion kinetics and 
tumor response of C-I CSH beads in tumor-bearing cats. 
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Figures and Tables: 
Figure 4.1A:  
A 10x10cm2 grid template with 5 concentric circles increasing in radii by 1cm were printed on 































Figure 4.1B (left image):  
The templates were placed over the clipped areas of the skin of each cat’s hemithorax and a mark 
placed on the skin using a sterile marker, for each of the proposed bead implantation sites. 
Figure 4.1C (right image):  
A small, 1.0 cm incision was made in the skin over each proposed implantation site with a #15 
scalpel blade. Metzenbaum scissors was used to gently dissect the subcutis to the cutaneous 
trunci muscle. Each bead was positioned and sutured into a small pocket of muscle by placement 
of a single, subcutaneous cruciate suture using 4-0 poliglecaprone-25. Incisions were closed with 
















Figure 4.2:  
A sterile 10x10cm2 grid template with 5 concentric circles increasing in radii by 1cm was placed 
over the clipped areas of the skin of each cat’s hemithorax and a mark placed on the skin using a 
sterile marker, for each proposed biopsy site. The sampling sites were at sites central to the beads 
and along concentric circles 1, 2, and 3 cm from the sites of bead implantation, a sham suture 


















Figure 4.3:  
All cats had grade 2-3 elevations in creatine phosphokinase [CPK], median 853.75 U/L, range 














Figure 4.4:  
All cats had abnormalities in serum calcium [Ca] levels with mild (grade 1) decreases in calcium 
in two cats and mild to moderate elevations in calcium (grades 1-2) in four cats, median Ca 10.7 







Figure 4.5:  
Serum concentrations peaked at 3mg/kg platinum (57.09 mg/m2 of calculated carboplatin at 2-3 
hours postimplantation (PI) and dropped to 0.5 mg/kg platinum (9.5 mg/m2 of calculated 












Figure 4.6:  
Based on the PK modeling, mean tissue platinum concentrations were highest on day 5 at the 
central biopsy site (3.35 mg/kg of platinum; 63.75 mg/m2 of calculated carboplatin). Between 
days 14 and 21, mean concentrations of both, cats and sites, were maintained at a concentration 
of 1.0 mg/kg of platinum (19.0 mg/m2 of calculated carboplatin), with the highest concentrations 


















































The pharmacokinetic (PK) parameters were evaluated by a 1-compartment with extravascular 
input model, C(t)=A(e-ket - e-kat), where C(t) is the measured platinum concentration at time t, ka 
and ka are the elimination (a.k.a. k10) and absorption (a.k.a. k01)  rate constants. A is a macro 
constant defined as Dka /V/( ka - ka), where D is the dose and V is the volume of distribution. By 
trial, we determined the best weight function was w = 1/ , where  is the estimated platinum 
concentration. Initial estimates of PK parameters were obtained for each distance for the data 
from all cats. Estimates for A, ka and ke were starting values to model the PK for each 
cat/distance combination. Starting values were adjusted by trial to obtain the best values for 
diagnostics (R2, AIC), and plausible estimates of Cmax, Tmax, clearance (Cl), and half-life (t1/2).  
Analysis of variance of these PK parameters, and area under the curve (AUC), was carried out to 
determine differences between distances.  Cat 1 was excluded from the analysis because mean 
platinum concentrations were increasing between day 14 and 21, while all other cats had a 
decrease in mean platinum concentrations. 
 
Parameter Unit 0 1 2 3 
t1/2ka d 1.659 3.02 4.63 0.09 
t1/2k10 d 10.465 13.09 4.93 54.68 
V/F (mg/kg)/(mg/kg) 0.451 0.61 0.27 1.75 
CL/F (mg/kg)/(mg/kg)/d 0.030 0.03 0.04 0.02 
Tmax d 5.238 8.32 6.89 0.87 
Cmax mg/kg 3.351 2.26 2.98 1.21 
AUC 0-t mg/kg*d 50.413 38.17 45.14 22.41 
AUC 0-inf mg/kg*d 71.565 66.41 55.90 96.42 
AUMC mg/kg*d^2 1251.728 1544.24 771.16 7620.15 
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